IOLCP Q3 & 9M FY26: Revenue ₹580.4 Cr, PBT ₹38.8 Cr, EBITDA ₹62.6 Cr
IOL Chemicals and Pharmaceuticals Limited reported Q3 FY26 standalone revenue of ₹580.4 crore, up 10.9% YoY. PBT increased by 39.3% to ₹38.8 crore, and EBITDA grew 22.8% to ₹62.6 crore. For 9M FY26, revenue was ₹1,699.6 crore, with PBT at ₹124.8 crore and EBITDA at ₹196.1 crore.
The results show positive financial performance with growth in key metrics, which is significant for investors. However, the impact is medium as it's a routine quarterly update and doesn't announce a major new development or a significant deviation from expectations.
The company reported year-on-year growth in revenue, PBT, and EBITDA for both the quarter and the nine-month period, indicating positive financial performance.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has presented its investor presentation for the third quarter and nine-month period ended December 31, 2025. The standalone revenue from operations for Q3 FY26 stood at ₹580.4 crore, marking a 10.9% year-on-year increase. Profit Before Tax (PBT) for the quarter was ₹38.8 crore, up 39.3% YoY, while EBITDA reached ₹62.6 crore, an increase of 22.8% YoY. The PBT margin improved to 6.6% from 4.7% in the prior year period.
For the nine-month period ended December 31, 2025 (9M FY26), revenue from operations was ₹1,699.6 crore, a 9.6% increase YoY. EBITDA for 9M FY26 grew by 24.8% YoY to ₹196.1 crore, and PBT rose by 34.2% YoY to ₹124.8 crore. The EBITDA margin for 9M FY26 was 11.4%, and the PBT margin was 7.3%.
The company also highlighted its historical growth, business overview, strategic shifts, and segment performance in pharmaceuticals and specialty chemicals. IOLCP emphasized its position as a leading global producer of Ibuprofen and its expansion into non-Ibuprofen APIs. The presentation also detailed its manufacturing facilities, R&D capabilities, certifications, management team, and ESG initiatives, including a commitment to becoming carbon neutral by 2050. The company has acquired additional land for future expansion and is focused on increasing its export revenue share.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.